However, clinical studies also found that some PD-L1 positive patients had poor feedback on immune checkpoint blockade, while others patients with negative PD-L1 were also able to respond (169), which provides a new requirement for further understanding the role of immune checkpoint in tumor immunotherapy to improve this strategy. The gene discussed is CD274; the disease is neoplasm.